LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) saw strong trading volume on Monday after Canaccord Genuity Group raised their price target on the stock from $15.00 to $16.00. Canaccord Genuity Group currently has a buy rating on the stock. Approximately 4,419,340 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 3,664,276 shares. The stock last traded at $13.8250 and had previously closed at $13.77.
LFST has been the topic of several other reports. KeyCorp upped their target price on LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday. JPMorgan Chase & Co. lifted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Barclays boosted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. BTIG Research increased their price objective on LifeStance Health Group from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.75.
Get Our Latest Research Report on LFST
Insider Buying and Selling at LifeStance Health Group
In related news, CTO Vukasin Paunovich sold 42,067 shares of LifeStance Health Group stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the sale, the chief technology officer owned 205,379 shares of the company’s stock, valued at approximately $2,643,227.73. The trade was a 17.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.
Hedge Funds Weigh In On LifeStance Health Group
Hedge funds have recently bought and sold shares of the business. Diversified Trust Co raised its holdings in LifeStance Health Group by 5.7% during the third quarter. Diversified Trust Co now owns 78,109 shares of the company’s stock valued at $940,000 after buying an additional 4,189 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of LifeStance Health Group by 10.7% in the third quarter. Fifth Third Bancorp now owns 180,736 shares of the company’s stock worth $2,174,000 after buying an additional 17,414 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of LifeStance Health Group by 80.5% during the 3rd quarter. Maryland State Retirement & Pension System now owns 60,294 shares of the company’s stock worth $725,000 after acquiring an additional 26,896 shares in the last quarter. Summit Creek Advisors LLC bought a new stake in shares of LifeStance Health Group during the 3rd quarter worth about $2,408,000. Finally, StoneX Group Inc. bought a new stake in shares of LifeStance Health Group during the 3rd quarter worth about $132,000. 85.50% of the stock is owned by institutional investors and hedge funds.
LifeStance Health Group Stock Performance
The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market cap of $5.29 billion, a P/E ratio of 72.82 and a beta of 1.35. The firm has a 50 day moving average price of $12.62 and a 200-day moving average price of $9.49.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The business had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. The firm’s revenue was up 25.3% compared to the same quarter last year. On average, research analysts predict that LifeStance Health Group, Inc. will post 0.17 EPS for the current year.
LifeStance Health Group Company Profile
LifeStance Health Group, Inc is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals.
Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders.
Founded in 2017, LifeStance has expanded its network across the United States.
Featured Stories
- Five stocks we like better than LifeStance Health Group
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
